Latest Insurance News

ColCap Financial Limited (ASX:TT6) reported a 16% rise in net profit to $72.2 million for FY2025, driven by a 15% expansion in its loan portfolio to $19.3 billion and a series of record Residential Mortgage-Backed Securities issuances.

RocketBoots has secured a significant A$3.3 million activation contract with a tier-one multinational retailer and reported over 50% growth in its early sales pipeline, supported by a strong cash position of A$5 million.

Kore Potash made steady progress on its Kola Potash Project in Q1 2026, completing key marine and topographic studies while navigating design revisions and ongoing financing talks. The company’s formal sale process continues with one bidder remaining active and cash reserves at US$8.3 million.

hipages Group (ASX:HPG) has kicked off an on-market buy-back of up to 10% of its shares, signalling confidence in its undervalued stock amid strong cash flow and growth.

hipages Group has acquired a majority stake in VIZ Insurance, marking its strategic entry into the insurance sector for tradies and broadening its platform offerings.

Control Bionics progresses its scalable distributor-led model in North America, inks a strategic US partnership for iOS speech devices, and gains German reimbursement eligibility for NeuroNode, while managing cash flow amid NDIS delays.

ImpediMed reported a $3.5 million revenue in Q3 FY26, with reimbursement coverage in the US reaching 94.3%, supporting growth in heart health and weight management markets. New CEO Erik Anderson aims to accelerate commercial momentum and drive cash flow break-even.

Argent BioPharma secured a 48% stake in CannPal Animal Therapeutics, shipped its largest CannEpil® order to Ireland worth A$783,000, and filed a US provisional patent for its NanoBodies platform, underpinning its neuro-immune strategy and commercial growth.

Emyria Limited is extending its Empax mental health clinic network into New South Wales through a new partnership with Matilda Nepean Private Hospital, increasing treatment capacity and national reach ahead of a planned Q3 2026 launch.

Botanix Pharmaceuticals reported a 5% rise in Sofdra prescriptions in Q3 FY26 despite a dip in net revenue due to insurance deductible resets, strengthened by a $45 million capital raise and a new API supply deal with Piramal.

Emyria reported $1.2 million revenue for Q1 2026 driven by insurer-funded clinics and expanded its Empax network across multiple states. It launched a Global Partnership Program targeting international drug sponsors, leveraging its clinical infrastructure amid growing global interest in psychedelic therapies.

FINEOS Corporation Holdings PLC reported its strongest quarterly cash inflow ever alongside key contract wins in Australia and North America, maintaining its FY26 revenue guidance and advancing AI integration in its insurance software platform.